1. A Survival Benefit for Reduced Intensity Allogeneic Transplants from Young Unrelated Donors Compared to Older Sibling Donors Depends on the Graft CD8 T-Cell Content 
Ran Reshef, MD, Austin P. Huffman, BA, Amy Gao, MS, Mary Sell, BS MT, Marlise R. Luskin, MD, Selina Luger, MD, Alison Loren, MD, MS, Elizabeth O. Hexner, MD, Sunita D. Nasta, MD, Noelle V. Frey, MD, Saar Gill, MBBS, PhD, James Mangan, MD PhD, Lee P. Richman, BA, Taku Kambayashi, MD PhD, Edward A. Stadtmauer, MD, Robert H. Vonderheide, MD DPhil, Rosemarie Mick, MS, David L. Porter, MD 
Biology of Blood and Marrow Transplantation 
Volume 21, Issue 2, Pages S42-S43 (February 2015)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Fig. 1 CD8 cell dose and overall survival.
Biology of Blood and Marrow Transplantation  , S42-S43DOI: ( /j.bbmt )
Copyright © Terms and Conditions

3. Fig. 2 Donor age and CD8 cell dose.
Biology of Blood and Marrow Transplantation  , S42-S43DOI: ( /j.bbmt )
Copyright © Terms and Conditions

4. Fig. 3
Survival of recipients (age>60) is better with young unrelated donors and a CD8hi graft.
Biology of Blood and Marrow Transplantation  , S42-S43DOI: ( /j.bbmt )
Copyright © Terms and Conditions